Pulmonx Co. (NASDAQ:LUNG) Stake Lifted by Trexquant Investment LP

Trexquant Investment LP lifted its position in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 510.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,700 shares of the company's stock after purchasing an additional 78,343 shares during the period. Trexquant Investment LP owned about 0.24% of Pulmonx worth $636,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in LUNG. R Squared Ltd purchased a new stake in Pulmonx during the 4th quarter worth $46,000. 272 Capital LP acquired a new stake in shares of Pulmonx during the third quarter valued at about $48,000. SG Americas Securities LLC increased its position in shares of Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after acquiring an additional 3,310 shares during the last quarter. American Century Companies Inc. increased its position in shares of Pulmonx by 8.8% during the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company's stock worth $236,000 after acquiring an additional 2,810 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Pulmonx by 4.9% in the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company's stock worth $363,000 after acquiring an additional 2,488 shares in the last quarter. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LUNG has been the subject of a number of recent analyst reports. Morgan Stanley began coverage on Pulmonx in a research note on Monday, March 10th. They set an "equal weight" rating for the company. Jefferies Financial Group initiated coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a "buy" rating for the company. D. Boral Capital assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a "buy" rating and a $17.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They set a "buy" rating for the company. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Pulmonx has a consensus rating of "Moderate Buy" and an average target price of $12.75.

Insiders Place Their Bets

In other Pulmonx news, CFO Mehul Joshi sold 14,384 shares of Pulmonx stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.12, for a total transaction of $102,414.08. Following the sale, the chief financial officer now owns 113,986 shares of the company's stock, valued at $811,580.32. The trade was a 11.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glendon E. French III sold 55,453 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total value of $459,150.84. Following the completion of the transaction, the director now directly owns 1,011,974 shares of the company's stock, valued at approximately $8,379,144.72. The trade was a 5.20 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 145,660 shares of company stock worth $1,128,484. Insiders own 5.70% of the company's stock.

Pulmonx Stock Performance

LUNG traded down $0.02 during trading on Thursday, reaching $4.77. 90,860 shares of the company were exchanged, compared to its average volume of 317,780. Pulmonx Co. has a 52 week low of $4.69 and a 52 week high of $10.01. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $7.11 and a 200 day moving average of $6.73. The stock has a market cap of $191.94 million, a P/E ratio of -3.31 and a beta of 0.61.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. On average, sell-side analysts forecast that Pulmonx Co. will post -1.55 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.